Compare WLFC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLFC | FTRE |
|---|---|---|
| Founded | 1985 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 864.4M |
| IPO Year | 1996 | N/A |
| Metric | WLFC | FTRE |
|---|---|---|
| Price | $134.05 | $15.76 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.36 |
| AVG Volume (30 Days) | 48.2K | ★ 1.4M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 17.99 | N/A |
| EPS | ★ 16.70 | N/A |
| Revenue | $674,381,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $16.17 | $3.17 |
| Revenue Next Year | $1.26 | $0.04 |
| P/E Ratio | $7.96 | ★ N/A |
| Revenue Growth | ★ 29.58 | 1.88 |
| 52 Week Low | $114.01 | $3.97 |
| 52 Week High | $229.67 | $20.86 |
| Indicator | WLFC | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 73.28 |
| Support Level | $126.56 | $14.02 |
| Resistance Level | $141.71 | $16.94 |
| Average True Range (ATR) | 5.21 | 1.08 |
| MACD | 1.77 | 0.24 |
| Stochastic Oscillator | 78.81 | 76.13 |
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.